Authors
Loading...
Randomized trial demonstrates high titer neutralizing antibody responses in mice using SARS-CoV receptor-binding domain, suggesting potential for vaccine development.
He et al. (2005) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: